Compare YELP & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YELP | DRTS |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2011 | N/A |
| Metric | YELP | DRTS |
|---|---|---|
| Price | $26.02 | $13.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $29.17 | $8.67 |
| AVG Volume (30 Days) | ★ 947.3K | 553.0K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.15 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $1,464,955,000.00 | N/A |
| Revenue This Year | $2.19 | N/A |
| Revenue Next Year | $2.34 | $699.98 |
| P/E Ratio | $83.47 | ★ N/A |
| Revenue Growth | ★ 3.75 | N/A |
| 52 Week Low | $19.60 | $3.01 |
| 52 Week High | $34.49 | $14.11 |
| Indicator | YELP | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 57.08 |
| Support Level | $23.87 | $11.24 |
| Resistance Level | $27.67 | $14.00 |
| Average True Range (ATR) | 1.16 | 0.80 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 26.07 | 69.05 |
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making appropriate buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States, and also has its presence in other countries.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.